Lakewood Amedex Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapeutics. The company's lead product, Nu-3, is in Phase 2 clinical trials for infected diabetic foot ulcers. They also have early-stage pipeline compounds targeting other indications like complicated urinary tract infections and pulmonary infections. Lakewood Amedex Biotherapeutics operates as a public company, having filed for a Nasdaq direct listing.
Lakewood Amedex Biotherapeutics' digital transformation focuses on strengthening its research and development data management and regulatory compliance infrastructure. This involves adopting specialized systems to handle complex clinical trial data, preclinical research data, and regulatory submissions. Their approach is distinct because it prioritizes robust, auditable data flows and stringent compliance within a lean operational model, leveraging external partnerships while maintaining rigorous internal oversight.
This transformation introduces critical dependencies on data integrity and system interoperability, creating challenges in maintaining consistent data across platforms and ensuring regulatory adherence. Risks include data discrepancies impacting clinical trial results and delays in regulatory approvals. This page analyzes Lakewood Amedex Biotherapeutics' key digital initiatives, the operational challenges they face, and potential sales opportunities for vendors addressing these specific breakdowns.
Lakewood Amedex Biotherapeutics Snapshot
Headquarters: University Park, FL, United States
Number of employees: 1-10 employees
Public or private: Public
Business model: B2B
Website: http://www.lakewoodamedex.com
Lakewood Amedex Biotherapeutics ICP and Buying Roles
Lakewood Amedex Biotherapeutics seeks solutions for companies managing highly regulated drug development and commercialization pipelines. They target partners who understand the complexities of clinical trials, regulatory submissions, and scientific data management.
Who drives buying decisions
- Chief Executive Officer → Sets strategic direction for technology adoption and compliance initiatives.
- Chief Medical Officer → Oversees clinical trial execution and data integrity.
- Head of Research and Development → Directs preclinical data management and scientific platforms.
- Head of Regulatory Affairs → Manages regulatory submission processes and compliance systems.
- CFO → Approves investments in financial reporting and compliance platforms for public company requirements.
Key Digital Transformation Initiatives at Lakewood Amedex Biotherapeutics (At a Glance)
- Implementing a Clinical Trial Management System.
- Adopting an Electronic Data Capture platform.
- Establishing a Regulatory Information Management system.
- Developing a central Preclinical Research Data repository.
- Upgrading Financial Reporting and Disclosure systems.
Where Lakewood Amedex Biotherapeutics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Trial Management Software | Clinical Trial Management System implementation: trial progress reports contain inconsistent patient enrollment data. | Chief Medical Officer, Head of Clinical Operations | Standardize data capture and aggregation across clinical sites. |
| Clinical Trial Management System integration: external CRO data does not synchronize with internal study records. | Head of Clinical Operations, VP of R&D | Unify clinical data from multiple external sources. | |
| Electronic Data Capture platform adoption: data entry forms lack real-time validation rules for patient demographics. | Head of Clinical Operations, Data Manager | Enforce data validation at the point of entry. | |
| Regulatory Compliance Platforms | Regulatory Information Management system implementation: document versions create conflicts before agency submission. | Head of Regulatory Affairs, Quality Assurance Lead | Maintain strict version control for all regulatory documents. |
| Regulatory Information Management system integration: submission packets miss required attachments from preclinical data. | Head of Regulatory Affairs, Head of R&D | Route all necessary data elements into submission compilations. | |
| Financial Reporting and Disclosure system upgrade: SEC filings include manual data reconciliation steps. | CFO, Controller | Automate data flows from general ledger to disclosure forms. | |
| Research Data Management Systems | Preclinical Research Data repository development: experimental results lack standardized metadata for future analysis. | Head of Research and Development, Data Scientist | Standardize metadata tagging and data structuring. |
| Preclinical Research Data repository integration: assay data does not link to sample tracking information. | Head of Research and Development, Lab Manager | Enforce data lineage from sample to result. | |
| Financial Management & ERP Solutions | Financial Reporting and Disclosure system upgrade: audit trails for financial transactions are incomplete. | CFO, Controller | Enforce complete transaction logging and access controls. |
Identify when companies like Lakewood Amedex Biotherapeutics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Lakewood Amedex Biotherapeutics’s digital transformation unique
Lakewood Amedex Biotherapeutics’s digital transformation prioritizes regulatory compliance and data integrity due to its public company status and clinical-stage drug development. This approach relies heavily on robust data management to support scientific validity and investor confidence. Their transformation is distinctive because it navigates intense regulatory scrutiny and complex scientific data requirements within a small organizational structure, necessitating highly integrated and auditable systems. They depend on precise data flows between internal research, external clinical partners, and regulatory bodies.
Lakewood Amedex Biotherapeutics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Clinical Data Management System Implementation
What the company is doing
Lakewood Amedex Biotherapeutics implements a Clinical Data Management System to centralize patient data from ongoing clinical trials. This system manages the collection, cleaning, and validation of information gathered during drug development. It consolidates diverse data points into a single, accessible platform for analysis.
Who owns this
- Chief Medical Officer
- Head of Clinical Operations
- Data Manager
Where It Fails
- Clinical data acquisition templates contain non-standardized fields across trial sites.
- Patient safety reporting workflows require manual data extraction before external submission.
- External Contract Research Organization (CRO) data does not map correctly to internal study protocols.
- Clinical data points show inconsistencies after database lock for statistical analysis.
Talk track
Noticed Lakewood Amedex Biotherapeutics implements Clinical Data Management Systems for ongoing trials. Been looking at how other biopharma teams standardize data inputs at the source instead of correcting errors later, happy to share what we’re seeing.
DT Initiative 2: Regulatory Information Management (RIM) System Adoption
What the company is doing
Lakewood Amedex Biotherapeutics adopts a Regulatory Information Management (RIM) system to organize and submit essential documents to health authorities. This system streamlines the preparation, tracking, and archiving of regulatory filings. It ensures all submission components meet specific governmental guidelines.
Who owns this
- Head of Regulatory Affairs
- Quality Assurance Lead
- Senior Legal Counsel
Where It Fails
- Regulatory submission packages miss critical documents after content compilation.
- Document control workflows allow unauthorized changes to approved regulatory text.
- Regulatory audit trails contain gaps in version history before external review.
- Submission deadlines are missed when document approvals stall in the workflow.
Talk track
Looks like Lakewood Amedex Biotherapeutics adopts Regulatory Information Management systems. Been seeing other biopharma companies enforce strict document versioning at every step to prevent submission errors, can share what’s working if useful.
DT Initiative 3: Preclinical Research Data Repository Development
What the company is doing
Lakewood Amedex Biotherapeutics develops a central Preclinical Research Data repository to store and organize early-stage scientific findings. This repository structures experimental results, compound information, and biological assay data. It supports long-term data accessibility and reusability for future research.
Who owns this
- Head of Research and Development
- Chief Scientific Officer
- Data Scientist
Where It Fails
- Preclinical data sets lack consistent naming conventions for experiment identifiers.
- Research data streams do not integrate directly from laboratory instruments.
- Assay results contain inconsistent units of measurement before analysis.
- Data provenance records for experimental samples are incomplete.
Talk track
Saw Lakewood Amedex Biotherapeutics develops a Preclinical Research Data repository. Been looking at how other research teams standardize metadata capture at the point of data generation, happy to share what we’re seeing.
DT Initiative 4: Financial Reporting and Compliance Automation
What the company is doing
Lakewood Amedex Biotherapeutics upgrades its Financial Reporting and Disclosure systems to meet public company requirements. This initiative automates data collection for financial statements, investor reports, and SEC filings. It implements controls to ensure data accuracy and auditability for external reporting.
Who owns this
- CFO
- Controller
- Head of Investor Relations
Where It Fails
- General Ledger data requires manual adjustments before quarterly report generation.
- Financial disclosures contain discrepancies between internal records and public statements.
- Audit log entries for financial transactions are insufficient for compliance checks.
- Consolidation of financial data from various departments creates reconciliation errors.
Talk track
Noticed Lakewood Amedex Biotherapeutics upgrades Financial Reporting and Disclosure systems. Been looking at how other public companies automate data validation at every reporting stage to prevent manual reconciliation, can share what’s working if useful.
Who Should Target Lakewood Amedex Biotherapeutics Right Now
This account is relevant for:
- Clinical Data Management System providers
- Regulatory Information Management (RIM) platforms
- Scientific Data Management and ELN/LIMS solutions
- Financial Reporting and Disclosure automation platforms
- Life Sciences Quality Management Systems
Not a fit for:
- Consumer-facing marketing analytics platforms
- General IT infrastructure hardware vendors
- Basic HR and payroll software
- Large-scale manufacturing ERP solutions (if not specific to small biopharma)
When Lakewood Amedex Biotherapeutics Is Worth Prioritizing
Prioritize if:
- You sell systems that integrate external CRO clinical data directly into internal trial management platforms.
- You sell platforms enforcing strict document version control for regulatory submissions.
- You sell solutions standardizing metadata capture for preclinical research data.
- You sell software automating financial data validation for public company reporting.
- You sell Quality Management Systems for GxP compliance in small biopharma.
- You sell tools for real-time audit trail generation across critical financial workflows.
Deprioritize if:
- Your solution does not address any of the breakdowns above.
- Your product is limited to basic functionality with no biopharma-specific compliance features.
- Your offering is not built for multi-system integration or auditable data environments.
Who Can Sell to Lakewood Amedex Biotherapeutics Right Now
Clinical Data & Operations Platforms
Veeva Systems - This company offers cloud-based software for the life sciences industry, including clinical operations and data management.
Why they are relevant: Clinical data acquisition templates contain non-standardized fields across trial sites, leading to data inconsistencies. Veeva Clinical Operations Suite can enforce standardized data capture protocols and integrate external CRO data directly, reducing manual reconciliation and improving data quality for Lakewood Amedex Biotherapeutics' trials.
Medidata Solutions - This company provides cloud-based solutions for clinical development, including electronic data capture and clinical trial management.
Why they are relevant: External CRO data does not map correctly to internal study protocols, causing delays in trial oversight. Medidata Rave EDC can standardize data collection forms and integrate diverse data sources, ensuring consistent patient enrollment data and accurate safety reporting for Lakewood Amedex Biotherapeutics.
Regulatory and Quality Management Systems
MasterControl - This company offers a quality management system (QMS) and regulatory solutions for life sciences organizations.
Why they are relevant: Regulatory audit trails contain gaps in version history, creating compliance risks before external review. MasterControl can provide a unified, auditable platform for document control and regulatory submissions, ensuring complete version histories and compliance with GxP regulations for Lakewood Amedex Biotherapeutics.
Qualio - This company provides a cloud-based electronic Quality Management System (eQMS) for regulated companies.
Why they are relevant: Document control workflows allow unauthorized changes to approved regulatory text, risking submission integrity. Qualio can enforce strict access controls and change management within regulatory document lifecycles, preventing unauthorized modifications and improving audit readiness for Lakewood Amedex Biotherapeutics.
Scientific Data Management & ELN/LIMS
LabKey Biologics - This company offers a LIMS designed for biopharma R&D data management, integrating assay data and electronic lab notebooks.
Why they are relevant: Preclinical data sets lack consistent naming conventions, hindering future analysis and data reusability. LabKey Biologics can standardize data inputs, enforce metadata tagging, and integrate research data directly from lab instruments, improving the structure and searchability of Lakewood Amedex Biotherapeutics' scientific findings.
Thermo Fisher Scientific (SampleManager LIMS) - This company provides Laboratory Information Management Systems (LIMS) for managing lab operations and data.
Why they are relevant: Research data streams do not integrate directly from laboratory instruments, causing manual transcription errors. SampleManager LIMS can automate data capture from lab equipment and enforce data provenance records, ensuring that assay results and sample tracking information are consistently linked for Lakewood Amedex Biotherapeutics.
Financial Management & Compliance Solutions
Sage Intacct - This company offers cloud financial management software tailored for life sciences, including grant tracking and financial reporting.
Why they are relevant: General Ledger data requires manual adjustments before quarterly report generation, increasing closing times. Sage Intacct can automate data flows from various financial sources, reducing manual reconciliation steps and accelerating accurate financial disclosures for Lakewood Amedex Biotherapeutics.
Workday Adaptive Planning - This company provides cloud-based planning, budgeting, and forecasting software.
Why they are relevant: Financial disclosures contain discrepancies between internal records and public statements, risking investor trust. Workday Adaptive Planning can provide a unified financial planning and reporting platform, ensuring consistent data across internal records and SEC filings through automated consolidation for Lakewood Amedex Biotherapeutics.
Final Take
Lakewood Amedex Biotherapeutics is rapidly scaling its clinical trials and regulatory submissions for novel anti-infective therapeutics. Breakdowns are visible in manual data reconciliation across clinical, regulatory, and financial systems, impacting compliance and reporting accuracy. This account presents a strong fit for vendors offering specialized solutions that automate data integrity, streamline GxP workflows, and ensure auditable financial disclosures within a highly regulated biopharma environment.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.